Fennec Pharmaceuticals Q3 EPS $(0.21) Misses $(0.10) Estimate, Sales $6.97M Miss $8.82M Estimate
Author: Benzinga Newsdesk | November 07, 2024 06:16am
Fennec Pharmaceuticals (NASDAQ:
FENC) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.10) by 110 percent. This is a 200 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $6.97 million which missed the analyst consensus estimate of $8.82 million by 20.93 percent. This is a 7.05 percent increase over sales of $6.51 million the same period last year.
Posted In: FENC